SCHEMBL5547788

SCHEMBL5547788

Cc1cc(C)c(-c2nc(CO[C]=O)cs2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
TP53 P04637 3/20 0.35
TSHR P16473 2/20 0.35
PKM P14618 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 6/20 0.33
KDM4E B2RXH2 3/20 0.33
HPGD P15428 3/20 0.33
MAPT P10636 3/20 0.33
LMNA P02545 2/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28015091 0.84 SMN1; SMN2 (0.41) SMN1; SMN2NPC1RAB9ATP53TSHR
SCHEMBL5541183 0.83 CYP17A1 (0.39) SMN1; SMN2NPC1RAB9ATP53TSHR
SCHEMBL5545431 0.75 PKM (0.46) SMN1; SMN2NPC1RAB9ATSHRPKM
SCHEMBL5546130 0.72 RAB9A (0.56) SMN1; SMN2NPC1RAB9ATP53TSHR
SCHEMBL5547627 0.70 ALDH1A1 (0.39) SMN1; SMN2NPC1RAB9ATP53TSHR
SCHEMBL5541827 0.70 GFER (0.60) SMN1; SMN2NPC1RAB9ATP53HSD17B10
SCHEMBL5537880 0.69 MAPT (0.42) NPC1RAB9ATSHRALDH1A1KDM4E
SCHEMBL5539297 0.69 SLC6A3 (0.41) SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL5535352 0.69 L3MBTL1 (0.61) SMN1; SMN2NPC1RAB9ATSHRMEN1
SCHEMBL5539775 0.69 ALDH1A1 (0.40) SMN1; SMN2NPC1RAB9ATP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SMN1; SMN2 3985/4885NPC1 2404/4885RAB9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.